137MO Outcomes of patients (pts) treated with ESCAT I–II targeted therapies (TT) in early phase clinical trials (EPCTs)

Year: 2026

Type: article

Abstract: TT and next-generation sequencing (NGS) have transformed cancer care, enabling personalized treatment approaches based on tumor molecular profiles. We evaluated outcomes of pts treated with ESCAT 1–2 matched agents in EPCTs within the 360 RESISTANCE (360R) study.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106280

Institutions: Vall d'Hebron Institute of Oncology, Vall d'Hebron Hospital Universitari

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910

Funder: “la Caixa” Foundation

Award: G7328500639

OpenAlex ID: W7147547106